Summary
Global
Markets Direct's, 'Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa EarlySecretory Antigenic Target or esxA) - Pipeline Review, H2 2016', provides in
depth analysis on Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early
Secretory Antigenic Target or esxA) targeted pipeline therapeutics.
The
report provides comprehensive information on the Mycobacterium tuberculosis
ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) , targeted
therapeutics, complete with analysis by indications, stage of development,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
report also covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press
releases. Additionally, the report provides an overview of key players involved
in Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory
Antigenic Target or esxA) targeted therapeutics development and features
dormant and discontinued projects.
Global
Markets Direct's report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
No comments:
Post a Comment